On the evening of August 27, the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards for China and Best Practices were grandly announced at the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards Ceremony and VIP Reception.
Based on recent research and analysis of the global immune cell therapy market, as well as studies and evaluations of related companies in the industry, Frost & Sullivan has awarded Frost & Sullivan Partner Robin Joffe, President of the Middle East, South Asia, and North Africa region, and Professor Wang Yu, Chairman of the China Liver Disease Prevention and Control Foundation, an expert advisor to the Frost & Sullivan Global Expert Advisory Group, and winner of the 2024 Frost & Sullivan Greater China Special Contribution Award, to represent Frost & Sullivan at the award ceremony for Shihui Biotechnology Co., Ltd. (hereinafter referred to as 'Shihui Biotech').
Gravel Biotechnology Co., Ltd.
"Global Immunotherapy Companies of the Year 2025"
Shale Biotech is an innovative biopharmaceutical company focusing on tumor immune cell therapy
Shale Biotech was established in 2019 and is headquartered in Shanghai. It is a leading innovative biopharmaceutical company in China, focusing on TIL (tumor-infiltrating lymphocytes) drugs, and deploying autologous and generic cell therapies. The company relies on StemTexp.®Dry TIL amplification, StaViral®Viral stable line, ImmuT Finder®Immunomodulatory target discovery, KOReTIL®The company has built four independent intellectual property platforms for efficient gene knockout, constructing a globally leading three-step product pipeline of 'non-editing - editing - universal'. The core variety GT101 has entered the critical Phase II clinical trial and is expected to become China's first commercial TIL therapy.
Accelerate the innovative clinical translation of TILs to bring breakthrough treatment options to patients with solid tumors
Gravel Biologics has deep cooperation with top centers such as the Cancer Hospital of the Chinese Academy of Medical Sciences and Fudan University Cancer Center, continuously promoting the evidence-based upgrading and industrialization implementation of TIL therapy in solid tumor fields such as cervical cancer and head and neck squamous cell carcinoma. In July 2025, GT201, the world's first membrane-bound IL-15 conjugate editing TIL drug, achieved complete remission in 6 months for patients with advanced head and neck squamous cell carcinoma; in the same year, the dual-gene knockout TIL therapy GT307, with ImmuT Finder®The newly identified immune regulatory targets on the platform have initially shown beneficial signals for cold tumors, marking that China's TIL innovation has entered the first tier globally.
The technology platform is leading, with a clear pipeline gradient and comprehensive coverage of autologous and general cell therapy needs.
The TIL drugs developed by Shale Biotechnology all utilize the independently established GMP-level process. Their outstanding advantages include: high cell viability, long-term persistence in vivo, strong tumor killing ability, good consistency between batches, and suitability for industrial large-scale production. Based on the platform technology, the company is also advancing simultaneously:
-
Autologous TILs: GT101 (non-genetic editing, key phase II trial for cervical cancer, expected to be submitted for marketing in 2026); GT201 (membrane-bound IL-15 editing, phase I clinical trial in China and the US); GT307 (double gene knockout, exploratory clinical trial for cryogenic tumors).
-
General-purpose cells: GT601 (AI novel antigen mRNA vaccine, with a 10-fold increase in predictive accuracy, currently in Phase IIT); GT719 (the world's first CAR-iNKT, with clinical data available, covering hematological malignancies and autoimmune diseases); GT801 (in vivo CAR-T, delivered via CLAMP-LNP without the need for chemoembolization, targeting autoimmune diseases).
About the Frost & Sullivan Global Annual Corporate Awards
The Frost & Sullivan Global Annual Corporate Award recognizes outstanding performance and achievements in areas such as technological innovation, market potential, customer service, and brand by companies. The Frost & Sullivan team has nominated a competitive group of excellent enterprises to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. The independent judging panel, composed of third-party investment and financing experts, financial experts, bankers, and renowned listed entrepreneurs, conducts a rigorous review of the enterprises nominated by the Frost & Sullivan team and has decided to award the '2025 Global Immune Cell Therapy Annual Corporate Award' to Shili Biotechnology Co., Ltd.
